The present disclosure relates to a deglycosylated antibody binding specifically to C-type lectin domain family 14, member A (clecl4a). More particularly, the present disclosure relates to a deglycosylated antibody that comprises a light chain variable region comprising CDR1 having a certain sequence and binds specifically to clec14, and use thereof, for example, a pharmaceutical composition containing the antibody for preventing or treating an angiogenesis-related disease.
